Paper4415565
Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.
Brady RO and 4 others. N Engl J Med, 1974. Cited by 235 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. Papers, record 4415565. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/4415565
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gaucher Disease | Major topic |
| Glucosidases | Major topic |
| Adolescent | |
| Biopsy | |
| Cerebrosides | |
| Chromatography, Thin Layer | |
| Erythrocytes | |
| Female | |
| Glucose | |
| Glycolipids | |
| Humans | |
| Injections, Intravenous | |
| Lipid Metabolism | |
| Lipids | |
| Liver | |
| Male | |
| Middle Aged | |
| Placenta |
Source PubMed
Cited by55
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 235 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39177874 | Targeting Neurological Aspects of Mucopolysaccharidosis Type II: Enzyme Replacement Therapy and Beyond. | BioDrugs | 2024 | https://conductscience.org/library/papers/39177874 | PubMed |
| 35706761 | Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases. | GEN Biotechnol | 2022 | https://conductscience.org/library/papers/35706761 | PubMed |
| 32070051 | Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32070051 | PubMed |
| 31836861 | Therapies for rare diseases: therapeutic modalities, progress and challenges ahead. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/31836861 | PubMed |
| 30128966 | Intra-monocyte Pharmacokinetics of Imiglucerase Supports a Possible Personalized Management of Gaucher Disease Type 1. | Clin Pharmacokinet | 2019 | https://conductscience.org/library/papers/30128966 | PubMed |
| 30103348 | Centronuclear myopathies under attack: A plethora of therapeutic targets. | J Neuromuscul Dis | 2018 | https://conductscience.org/library/papers/30103348 | PubMed |
| 29848835 | Enzyme replacement therapy in India: Lessons and insights. | J Postgrad Med | 2018 | https://conductscience.org/library/papers/29848835 | PubMed |
| 29670214 | Restoring functional neurofibromin by protein transduction. | Sci Rep | 2018 | https://conductscience.org/library/papers/29670214 | PubMed |
| 28502768 | Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives. | Adv Drug Deliv Rev | 2017 | https://conductscience.org/library/papers/28502768 | PubMed |
| 28314976 | Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923-2016). | J Inherit Metab Dis | 2017 | https://conductscience.org/library/papers/28314976 | PubMed |
| 28207759 | Investigations on therapeutic glucocerebrosidases through paired detection with fluorescent activity-based probes. | PLoS One | 2017 | https://conductscience.org/library/papers/28207759 | PubMed |
| 27916601 | Gaucher disease: Progress and ongoing challenges. | Mol Genet Metab | 2017 | https://conductscience.org/library/papers/27916601 | PubMed |
| 27790078 | Imiglucerase in the management of Gaucher disease type 1: an evidence-based review of its place in therapy. | Core Evid | 2016 | https://conductscience.org/library/papers/27790078 | PubMed |
| 27384562 | Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders. | Int J Mol Sci | 2016 | https://conductscience.org/library/papers/27384562 | PubMed |
| 27098312 | Progress and potential of non-inhibitory small molecule chaperones for the treatment of Gaucher disease and its implications for Parkinson disease. | Expert Rev Proteomics | 2016 | https://conductscience.org/library/papers/27098312 | PubMed |
| 26471939 | Diagnosis and treatment of late-onset Pompe disease in the Middle East and North Africa region: consensus recommendations from an expert group. | BMC Neurol | 2015 | https://conductscience.org/library/papers/26471939 | PubMed |
| 26260077 | Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. | Mol Genet Metab | 2015 | https://conductscience.org/library/papers/26260077 | PubMed |
| 24534703 | The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases. | J Lipid Res | 2014 | https://conductscience.org/library/papers/24534703 | PubMed |
| 24531622 | Glucocerebrosidase is shaking up the synucleinopathies. | Brain | 2014 | https://conductscience.org/library/papers/24531622 | PubMed |
| 23554863 | Liver fibrosis in type I Gaucher disease: magnetic resonance imaging, transient elastography and parameters of iron storage. | PLoS One | 2013 | https://conductscience.org/library/papers/23554863 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/4415565
GET https://conductscience.org/api/papers/v1/4415565/cited_by?page=2